A novel vaccination approach developed by Vanderbilt Health researchers cleared the harmful gut bacterium Clostridioides ...

As antibiotic resistance grows, so does research toward preventing and treating Clostridioides difficile, a bacterium known to be one of the leading causes of healthcare-associated infections in U.S.

Newly discovered iron storage 'ferrosomes' inside the bacterium C. diff -- the leading cause of hospital-acquired infections -- are important for infection in an animal model and could offer new ...

Recurrent C. diff infection is when you contract a C. diff infection 2 to 8 weeks after completing treatment for a previous one. C. diff relapse is a recurrence of the same strain, while reinfection ...

At the end of 2010, Ellis Hospital noticed a troubling spike in Clostridium difficile infections. Clostridium difficile, or C-diff, is a common cause of diarrhea acquired in healthcare settings; it ...

Antibiotic stewardship programs may be key element of managing Clostridium difficile infections among patients suffering from osteoarticular infections, according to a study published in Antimicrobial ...

The Food and Drug Administration has approved a fecal microbiota pill to treat recurrent infections caused by Clostridium difficile (C. diff), an antibiotic-resistant bacterium deemed an urgent threat ...

Researchers at the Texas A&M University Health Science Center (Texas A&M Health) have uncovered why C. diff (also known as Clostridioides difficile or C. difficile) infection has developed resistance ...

A new antibiotic to fight the deadly "superbug" C. diff has proved effective in clinical trials. Treating patients with ibezapolstat provided high rates of "sustained" clinical cures, say American ...

Clostridiumdifficile infection (also known as C. diff or CDI) is one of the most common hospital-acquired infections and is a frequent cause of death among hospitalized older adults. Keystone ...

This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of The ...

Mikrobiomik has become the first organisation in Spain to receive authorisation to prepare and process faecal microbiota for treating Clostridioides difficile infection, following approval of its oral ...